Compare Global X Autonomous & Electric Vehicles (DRIV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Recursion Pharmaceuticals Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.79 (market cap $356.37M), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 6× Global X Autonomous & Electric Vehicles's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 22,397). Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DRIV | RXRX | |
|---|---|---|
Market Cap | $356.37M | $2.14B |
Volume | 22,397 | 30,789,535 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $6.79 |
52-Week Low | $27.58 | $2.84 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $32.60, down 2.29% today amid mixed technical signals with a bullish overall signal but bearish moving averages. The stock shows neutral momentum oscillators with RSI at 51.36 indicating balanced buying and selling pressure. Recent automotive sector news highlights hybrid vehicle momentum and China's ambitious EV targets, potentially benefiting automotive-focused ETFs.
The stock faces near-term resistance at $34 with technical indicators suggesting consolidation. Automotive sector transformation creates both opportunities from EV/hybrid adoption and risks from oil price volatility. Market sentiment remains divided as investors weigh technological shifts against traditional automotive challenges.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
